Patents Assigned to Yissum Research Development Co.
  • Patent number: 5849742
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction and particularly KDR/FLK-1 receptor signal transduction in order to regulate and/or modulate vasculogenesis and angiogenesis. The invention is based, in part, on the demonstration that KDR/FLK-1 tyrosine kinase receptor expression is associated with endothelial cells and the identification of vascular endothelial growth factor (VEGF) as the high affinity ligand of FLK-1. These results indicate a major role for KDR/FLX-1 in the signaling system during vasculogenesis and angiogenesis. Engineering of host cells that express FLK-1 and the uses of expressed FLK-1 to evaluate and screen for drugs and analogs of VEGF involved in FLK-1 modulation by either agonist or antagonist activities is also described.
    Type: Grant
    Filed: May 9, 1997
    Date of Patent: December 15, 1998
    Assignees: Sugen Inc., Yissum Research Development Co. of The Hebrew Universuty of Jerusalem
    Inventors: Harald App, Gerald M. McMahon, Peng Cho Tang, Aviv Gazit, Alexander Levitzki
  • Patent number: 5837814
    Abstract: A cellulose binding domain (CBD) having a high affinity for crystalline cellulose and chitin is disclosed, along with methods for the molecular cloning and recombinant production thereof. Fusion products comprising the CBD and a second protein are likewise described. A wide range of applications are contemplated for both the CBD and the fusion products, including drug delivery, affinity separations, and diagnostic techniques.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: November 17, 1998
    Assignees: Yissum Research Development Co. of Hebrew University Of Jeruslame, University of CA
    Inventors: Oded Shoseyov, Itai Shpiegl, Marc Goldstein, Roy Doi
  • Patent number: 5811392
    Abstract: Novel backbone cyclized peptide analogs are formed by means of bridging groups attached via the alpha nitrogens of amino acid derivatives to provide novel non-peptidic linkages. Novel building units disclosed are N.sup..alpha. (.omega.-functionalized) amino acids constructed to include a spacer and a terminal functional group. One or more of these N.sup..alpha. (.omega.-functionalized) amino acids are incorporated into a peptide sequence, preferably during solid phase peptide synthesis. The reactive terminal functional groups are protected by specific protecting groups that can be selectively removed to effect either backbone-to-backbone or backbone-to-side chain cyclizations. The invention is exemplified by backbone cyclized bradykinin antagonists having biological activity. Further embodiments of the invention are somatostatin analogs having one or two ring structures involving backbone cyclization.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 22, 1998
    Assignees: Yissum research Development Co. of the Hebrew University, Peptor Limited
    Inventors: Chaim Gilon, Doron Eren, Irina Zeltser, Alon Seri-Levy, Gal Bitan, Dan Muller
  • Patent number: 5792771
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction and particularly KDR/FLK-1 receptor signal transduction in order to regulate and/or modulate vasculogenesis and angiogenesis. The invention is based, in part, on the demonstration that KDR/FLK-1 tyrosine kinase receptor expression is associated with endothelial cells and the identification of vascular endothelial growth factor (VEGF) as the high affinity ligand of FLK-1. These results indicate a major role for KDR/FLK-1 in the signaling system during vasculogenesis and angiogenesis. Engineering of host cells that express FLK-1 and the uses of expressed FLK-1 to evaluate and screen for drugs and analogs of VEGF involved in FLK-1 modulation by either agonist or antagonist activities is also described.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: August 11, 1998
    Assignees: Sugen, Inc., Yissum Research Development Co. of the Hebrew University of Jerusalem
    Inventors: Harald App, Gerald M. McMahon, Peng Cho Tang, Aviv Gazit, Alexander Levitzki
  • Patent number: 5776970
    Abstract: Tryptophan derivatives substituted by a hydrophobic group, e.g. carbobenzoxy, at the N-terminus, and a hydrophilic group, e.g. --COOH, --SO.sub.3 H or --PO.sub.3 H, at the C-terminus, were found to be cell-permeable blockers of protein tyrosine kinases (PTKs). These PTK blockers are useful in basic research and in the treatment of neoplastic diseases.
    Type: Grant
    Filed: April 28, 1994
    Date of Patent: July 7, 1998
    Assignees: Yeda Research and Development Co. Ltd., Yissum Research Development Co.
    Inventors: Yoram Shechter, David Naor
  • Patent number: 5766861
    Abstract: A method for screening or detection of a non-enzyme catalytic polypeptide or protein for the conversion of a substrate S to a product P is provided, in which a preparation containing the potential catalyst is contacted with the substrate S immobilized to a support and the immobilized product P obtained is detected, preferably by immunoassay. The method is preferably used for the screening of hybridoma supernatants for catalytic monoclonal antibodies that catalyze acyl transfer reactions, e.g., hydrolysis or aminolysis, condensation reactions and resolution of enantiomers.
    Type: Grant
    Filed: August 22, 1995
    Date of Patent: June 16, 1998
    Assignees: Yeda Research and Development Company Ltd., Yissum Research and Development Co. of the Hebrew University of Jerusalem
    Inventors: Zelig Eshhar, Bernard S. Green, Dan S. Tawfik
  • Patent number: 5753612
    Abstract: Pharmaceutical preparations for controlling proliferation of ectodermally-derived tissues comprising the specific negative growth factor activin A or an agonist thereof, and their use in methods of treatment of proliferative conditions and wound repair.
    Type: Grant
    Filed: February 7, 1995
    Date of Patent: May 19, 1998
    Assignee: Yissum Research Development Co. of the Hebrew University of Jerusalem
    Inventor: Eduardo Mitrani
  • Patent number: 5726039
    Abstract: The invention relates to an expression vector, the nucleic acid sequence of which comprises a promoter that is capable of controlling, when the vector is in a bacterial host and the temperature is lowered to below about 20.degree. C., the production of recombinant peptide or protein encoded by a gene contained within the vector. The invention also relates to host cells containing the vectors and to a method of producing a recombinant protein.
    Type: Grant
    Filed: July 20, 1995
    Date of Patent: March 10, 1998
    Assignee: Yissum Research Development Co. of The Hebrew University of Jerusalem
    Inventors: Amos B. Oppenheim, Hilla Giladi, Daniel Goldenberg, Simi Kobi, Idit Azar
  • Patent number: 5719264
    Abstract: The present invention is directed to conotoxin peptides having 25-35 amino acids, six cysteines which form three disulfide bonds between the first and fourth, second and fifth, and third and sixth cysteines, respectively. The invention is directed to .delta.-conotoxin GmVIA having the formula Val-Lys-Pro-Cys-Arg-Lys-Glu-Gly-Gln-Leu-Cys-Asp-Pro-Ile-Phe-Gln-Asn-Cys-Cy s-Arg-Gly-Trp-Asn-Cys-Val-Leu-Phe-Cys-Val (SEQ ID NO:1). This peptide activates sodium channels. The invention is further directed to .mu.O-conotoxin peptides of the generic formula Ala-Cys-Xaa.sub.1 -Lys-Lys-Trp-Glu-Tyr-Cys-Ile-Val-Pro-Ile-Xaa.sub.2 -Gly-Phe-Xaa.sub.3 -Tyr-Cys-Cys-Pro-Gly-Leu-Ile-Cys-Gly-Pro-Phe-Val-Cys-Val, wherein Xaa.sub.1 is Arg or Ser, Xaa.sub.2 is Ile or Leu and Xaa.sub.3 is Ile or Val (SEQ ID NO:2). These peptides block sodium charmels. Examples of .mu.
    Type: Grant
    Filed: October 7, 1994
    Date of Patent: February 17, 1998
    Assignees: Univ. of Utah Research Foundation, Yissum Research Development Co. of the Hebrew University of Jerusalem
    Inventors: Ki-Joon Shon, Baldomero M. Olivera, J. Michael McIntosh, Arik Hasson, Micha E. Spira
  • Patent number: 5707736
    Abstract: The invention provides a dry, disposable, polymeric product having sustained-release anti-microbial activity, the product consisting essentially of a polymeric material selected from the group consisting of fibers, fabrics, sheets, films and other stable woven, non-woven and knitted materials prepared from natural, man-made and synthetic polymers and an amine salt anti-microbial agent, the anti-microbial agent being incorporated in the polymeric material without an intermediary adhesive, carrier or linking agent and being releasable therefrom in anti-microbially effective amounts for a period of at least three days upon the product being brought into contact with a moist surface.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: January 13, 1998
    Assignees: Sion Texo Medic Ltd., Yissum Research Development Co. of Hebrew Univ. of Jerusalem, Israel Fiber Institute
    Inventors: David Levy, Hilda Guttmann, Itzhak Kahane
  • Patent number: 5630978
    Abstract: A method for preparing mimics of a wide variety of drugs and other biologically active molecules using molecular imprinting techniques, and the mimics produced thereby, is disclosed. Specifically, the mimic is designed by: (i) polymerization of functional monomers around a known drug or biologically active molecule (the template) that exhibits a desired activity; (ii) removal of the template molecule; and then (iii) polymerization of a second class of monomers in the void left by the template, to provide a new organic molecule which exhibits one or more desired properties which are similar to that of the template.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 20, 1997
    Assignee: Yissum Research Development Co. of The Hebrew University of Jerusalem
    Inventor: Abraham J. Domb
  • Patent number: 5614375
    Abstract: The invention provides a method for the rapid detection of biotoxic contaants in a test material comprising combining a sample of the test material with activated spores essentially devoid of detectable enzymatic activity, which activity becomes manifest and increases measurably following germination of the spores and with at least one germinant capable of triggering germination of the spores and a substrate which is catalytically convertible to a product by the enzymatic activity, incubating the mixture for a period of less than one hour to accelarate germination of the spores, increase of the enzyme activity, and a catalytic conversion of the substrate, and detecting the formation of the product of the catalytic conversion of the substrate and the enzyme, the level of the product being maximal in the absence of any biotoxic contaminants, and decreasing in direct proportion to the toxicity of contaminants in the test sample.
    Type: Grant
    Filed: March 23, 1994
    Date of Patent: March 25, 1997
    Assignee: Yissum Research Development Co. of the Hebrew University of Jerusalem
    Inventor: Nathan Citri
  • Patent number: 5595903
    Abstract: Genetically engineered human acetylcholinesterase and antibodies that def the protein are described. These composition may be used in pharmaceutical preparations for treatment and prophylaxis of organo-phosphorous compound poisoning or post-operative apnea. Also described are human cholinesterase DNA probes which may be employed for diagnosing progressing ovarian carcinomas and hemocytopoietic disorders.
    Type: Grant
    Filed: August 2, 1993
    Date of Patent: January 21, 1997
    Assignee: Yissum Research Development Co. of the Hebrew University of Jerusalem
    Inventors: Hermona Soreq, Zakut Haim
  • Patent number: 5552139
    Abstract: A method for the biological control of pollen in plants, including the thinning of fruits, reducing seeds in citrus plants and reducing the incidence of shotberries in grapes, by applying an effective amount of activated or inactivated RNase or mixtures of these to the flowers of the plants.
    Type: Grant
    Filed: November 4, 1993
    Date of Patent: September 3, 1996
    Assignee: Yissum Research Development Co. of the Hebrew University of Jerusalem
    Inventors: Oded Shoseyov, Levava Roiz, Uzi Ozeri, Ben-Ami Bravdo, Raphael Goren
  • Patent number: 5525634
    Abstract: A colonic delivery system for delivering a drug to the colon is provided. The system comprises a drug in combination with a matrix, wherein the matrix comprises a saccharide-containing polymer. According to the invention, the matrix is resistant to chemical and enzymatic degradation in the stomach and small intestine. The matrix is degraded in the colon by bacterial enzymatic action, and the drug is released. The system is useful for targeting drugs to the colon in order to treat colonic disease. The system is also useful for enteric administration of drugs such as proteins and peptides which are otherwise degraded in the stomach and small intestine.
    Type: Grant
    Filed: February 10, 1994
    Date of Patent: June 11, 1996
    Assignees: Perio Products, Ltd., Yissum Research Development Co. of the Hebrew Univ. of Jerusalem
    Inventors: Amnon Sintov, Abraham Rubinstein
  • Patent number: 5486591
    Abstract: A monomeric diacid derivative includes at least two fatty acids coupled by hydrolytically or enzymatically degradable bond. In a biological environment, the bond degrades forming naturally occurring fatty acid products thereby allowing elimination.
    Type: Grant
    Filed: March 21, 1995
    Date of Patent: January 23, 1996
    Assignee: Yissum Research Development Co. of the Hebrew University of Jerusalem
    Inventors: Abraham J. Domb, Raphael Nudelman
  • Patent number: 5473103
    Abstract: A monomeric diacid derivative includes at least two fatty acids coupled by a hydrolytically or enzymatically degradable bond. In a biological environment, the bond degrades forming naturally occurring fatty acid products thereby allowing elimination.
    Type: Grant
    Filed: December 16, 1993
    Date of Patent: December 5, 1995
    Assignee: Yissum Research Development Co. of the Hebrew University of Jerusalem
    Inventors: Abraham J. Domb, Raphael Nudelman
  • Patent number: 5430058
    Abstract: Pharmaceutical compositions comprising compounds of the formula: R.sup.2 C{CH.sub.2 O(CH.sub.2).sub.n CO[NR.sup.3 CHR(CH.sub.2).sub.m CO].sub.q NOHR.sup.1 }.sub.3, wherein R is hydrogen, alkyl optionally substituted by OR.sup.5, SR.sup.5, NR.sup.5 R.sup.6, COR.sup.6, COOR.sup.6, CONR.sup.5 R.sup.6, --NHC(NR.sup.5 R.sup.6).dbd.NR.sup.7, aryl, aralkyl or heteroaryl; R.sup.1, R.sup.2 and R.sup.3 are independently selected from the group consisting of hydrogen, alkyl, aralkyl, aryl, COOR.sup.4, CONHR.sup.4 and CONR.sup.4 R.sup.4 ; R.sup.2 may additionally be alkyl substituted by alkoxy, alkenyloxy or by a group --O--(CH.sub.2).sub.p --COOX or --O--(CH.sub.2).sub.p --CONHX, wherein p is an integer from 1 to 10 and X is alkyl, aralkyl, aryl or heteroaryl; R.sup.4, R.sup.5 and R.sup.6 are hydrogen, alkyl, aralkyl, aryl or heteroaryl; n is 1 or 2, m is 0, 1 or 2 and q is 0 or 1, and when m is 0, the moiety --NR.sup.
    Type: Grant
    Filed: March 1, 1993
    Date of Patent: July 4, 1995
    Assignees: Yeda Research and Development Co. Ltd., Yissum Research and Development Co. of the Hebrew University of Jerusalem
    Inventors: Abraham Shanzer, Jacqueline Libman, Ioav Z. Cabantchik
  • Patent number: 5387576
    Abstract: Pharmaceutical preparations for the treatment of hyperproliferative epidermal conditions comprising the specific negative growth factor activin A, and their use in methods of treatment of hyperproliferative epidermal conditions.
    Type: Grant
    Filed: October 27, 1992
    Date of Patent: February 7, 1995
    Assignee: Yissum Research Development Co.
    Inventor: Eduardo Mitrani
  • Patent number: 4876276
    Abstract: The invention relates to novel (3S,4S)-7-hydroxy-.DELTA..sup.6 -tetrahydrocannabinol homologes and derivatives, essentially free of the (3R,4R) form and to pharmaceutical compositions which have a potent analgetic, antiemetic and antiglaucoma effect, which compositions contain an effective dosage of a compound of this type. The novel pharmaceutical compositions are practically devoid of the undesired side effects of the (3R,4R) type compounds, such as cannabimimetic psychotropic effects. The pharmaceutical compositions are of special utility in cases of acute and of chronic pain. The invention also relates to a process for the production of the above defined novel compounds.
    Type: Grant
    Filed: October 26, 1987
    Date of Patent: October 24, 1989
    Assignee: Yissum Research Development Co. of The Hebrew University of Jerusalem
    Inventors: Raphael Mechoulam, Jeffery J. Feigenbaum, Naphtali Lander, Morris Srebnik